MedTrace Logo

Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer

NCT00530868 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2022-10-21

Study results available
· View outcomes & findings →

Summary

This purpose of this trial is to show that the combination of Avastin and hormone therapy should be more effective than hormone therapy alone for the treatment of breast cancer.

Conditions

Interventions

OTHER

Letrozole (Femara)

Letrozole 2.5 mg PO a day for 24 weeks

DRUG

Letrozole; Avastin

Letrozole 2.5 mg PO a day and Avastin 15 mg/kg IV every 3 weeks

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Breast Cancer Research Foundation

    collaborator OTHER

  • University of Alabama at Birmingham

    lead OTHER

Principal Investigators

  • Lisle Nabell, M.D. · University of Alabama at Birmingham

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-08
Primary Completion
2022-03-01
Completion
2022-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00530868 on ClinicalTrials.gov